Equities

Voyageur Pharmaceuticals Ltd

VYYRF:PKC

Voyageur Pharmaceuticals Ltd

Actions
  • Price (USD)0.0405
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 12 2024 18:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-1.30m
  • Incorporated2008
  • Employees--
  • Location
    Voyageur Pharmaceuticals LtdDome Tower 800, 333 7 Ave. S.W.CALGARY T2P 2Z1CanadaCAN
  • Phone+1 (403) 923-5944
  • Fax+1 (403) 508-2670
  • Websitehttps://voyageurpharmaceuticals.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.